There is a high unmet need for patients with EGFR-mutant non-small cell lung cancer (NSCLC) that have developed resistance to EGFR inhibitors. Liam and colleagues present final analyses from the phase II part of INSIGHT, evaluating tepotinib (a once-daily, highly selective MET inhibitor) plus gefitinib versus chemotherapy in patients with EGFR-mutant NSCLC and MET-driven EGFR inhibitor resistance, with a median follow-up duration of 57.5 months. This long follow-up emphasizes that the greatest benefit from tepotinib plus gefitinib is derived by patients with MET amplification, who showed substantially improved progression-free and overall survival versus chemotherapy in this updated analysis. Furthermore, all patients who received long-term tepotinib plus gefitinib had MET amplification, with 25% of patients with MET amplification receiving combination treatment for >4 years, and 17% for >5 years (including continuing treatment outside the study). Tepotinib plus an EGFR inhibitor is a promising strategy in this disease setting.

Older patients with...

You do not currently have access to this content.